Drug intelligence / Profile preview

HBP01

Development stage: Preclinical
Lead developer: HealthBiome
Modality: Peptides
Administration: Oral

Overview

HBP01 is a therapeutic peptide derived from the commensal gut bacterium *Akkermansia muciniphila*, currently in preclinical development by HealthBiome for the treatment of inflammatory bowel disease (IBD). Unlike live biotherapeutic products (LBPs) that utilize whole bacterial strains, HBP01 is a specific bioactive peptide designed to modulate intestinal inflammation and host–microbiome interactions. The drug aims to restore intestinal barrier function and immune homeostasis by targeting the inflammatory pathways associated with chronic gut disorders. As a microbiome-derived peptide, it represents a targeted approach to leveraging the beneficial effects of the gut microbiota in a defined molecular format.

Other names: Peptide derived from Akkermansia muciniphila

Beyond the preview

Go deeper on HBP01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HBP01.

Explore the full profile